Johnson & Johnson's Covid-19 vaccine receives emergency use approval in India
text_fields
New Delhi:The healthcare brand Johnson & Johnson receives emergency use authorisation for its single-dose Covid-19 vaccine in India.
Union Health Minister Mansukh Mandaviya tweeted on Saturday that the Johnson & Johnson is the fifth Covid-19 vaccine to receive EUA in India as the country is expanding its vaccine basket.He added that the new vaccine will further boost the nation's collective fight against Covid-19.
India has so far vaccinated 50.10 crore people, he added.
Meanwhile, in its submission for EUA, Johnson & Johnson shared data from the Phase 3 ENSEMBLE clinical trial which demonstrates that the vaccine is 85% effective in preventing Covid-19.
Johnson & Johnson on Friday announced that getting EUA is an important milestone that paves the way for bringing the company's single-dose COVID-19 vaccine to the people of India, and the rest of the world, through a collaboration with Biological E Limited.
The company statement read that Biological E will be an important part of J&J's global supply chain network. This will help the firm to supply vaccines through extensive collaborations, partnerships with governments, and organisations like Gavi and COVAX Facility, it said.
Apparently, Johnson & Johnson's vaccine is easier to handle than other international vaccines like Pfizer and Moderna as they easily lasts about three months in the refrigerator.
The single-dose vaccine, estimated to remain stable for two years at -4°F (-20°C), and a maximum of 4.5 months at routine refrigeration temperatures of 36° to 46°F (2° to 8°C), informed WHO.